Nanobac Pharmaceuticals(OTC) NNBP

Nanobac Pharmaceuticals, Incorporated is focused on enhancing human health through innovative products aimed at identifying and managing calcifying nanoparticles (CNPs). The company specializes in in vitro diagnostic (IVD) kits, including assays and reagents for CNP detection, and conducts research on various urological and cardiovascular diseases.

Products and Services

• In vitro diagnostic (IVD) kits for CNP detection
• NANO-CAPTURE and NANO-SERO diagnostic assays
• Research on urological diseases and cardiovascular conditions

Growth Outlook

• Continued focus on expanding diagnostic capabilities in urological diseases
• Potential for partnerships in the biotechnology sector to enhance research
• Growing market demand for innovative diagnostic solutions

Financial Highlights

• Recent quarterly revenue of 4,368, indicating a steady operational base
• Trailing twelve months (TTM) gross profit margin at 17.6%, showcasing product viability
• Operating income margin of 278.9%, reflecting strong operational efficiency

Nanobac Pharmaceuticals, Incorporated, established in 1994 and headquartered in Tampa, Florida, has a unique position in the biotechnology industry. The company’s commitment to developing diagnostic tools for CNPs addresses a significant need in healthcare, particularly in urology and cardiovascular health. The recent quarterly revenue indicates a stable operational foundation, while the gross profit margin suggests that the products are well-received in the market. The impressive operating income margin highlights the company's ability to manage costs effectively, which is crucial for long-term sustainability. As the demand for innovative diagnostic solutions continues to rise, Nanobac is well-positioned to capitalize on emerging opportunities in the biotechnology sector.